Ronnie T.P. Poon

Medicine · Health Sciences

45h-index7.8kcitations125works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(69), Liver Disease Diagnosis and Treatment(23), Cholangiocarcinoma and Gallbladder Cancer Studies(18), Cancer, Hypoxia, and Metabolism(17), Cancer Mechanisms and Therapy(13)

Publications124 total

Supplementary Tables from A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
2023Open Access
Supplementary Figure 1 from A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
2023Open Access
Data from A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
2023Open Access
Supplementary Figure 1 from A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
2023Open Access
Supplementary Figure Legends 1-6 from The Kringle 1 Domain of Hepatocyte Growth Factor Has Antiangiogenic and Antitumor Cell Effects on Hepatocellular Carcinoma
2023Open Access
Supplementary Figures 1-6 from The Kringle 1 Domain of Hepatocyte Growth Factor Has Antiangiogenic and Antitumor Cell Effects on Hepatocellular Carcinoma
2023Open Access
Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts
Cancer Science·2019· 61 citedOpen Access
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
British Journal of Cancer·2018· 31 citedOpen Access
Abstract 4389: <i>TSC1/2</i> mutations define a molecular subset of HCC with aggressive behavior and treatment implication
Cancer Research·2017
Does hepatitis B seroconversion affect survival outcome in patients with hepatitis B related hepatocellular carcinoma?
Translational Gastroenterology and Hepatology·2016· 1 citedOpen Access
Differences in health‐related quality of life between European and Asian patients with hepatocellular carcinoma
Asia-Pacific Journal of Clinical Oncology·2016· 13 cited
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
The Lancet Oncology·2015· 1.1k cited
Pure Laparoscopic Versus Open Left Lateral Sectionectomy for Hepatocellular Carcinoma: A Single‐Center Experience
World Journal of Surgery·2015· 34 cited
Quality of life changes in patients undergoing treatment for hepatocellular carcinoma
Quality of Life Research·2015· 32 cited
Genome-wide identification of RNA editing in hepatocellular carcinoma
Genomics·2014· 40 cited
Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence
Seminars in Liver Disease·2014· 67 cited
Abstract 552: Genetic polymorphisms of the drug transporter ABCB5 associated with advanced liver cancer
Cancer Research·2014
Hepatocellular Carcinoma: Surveillance CT Schedule after Hepatectomy Based on Risk Stratification
Radiology·2014· 30 cited
Survivin depletion inhibits tumor growth and enhances chemosensitivity in hepatocellular carcinoma
Molecular Medicine Reports·2014· 18 citedOpen Access
Defining an optimal surgical strategy for synchronous colorectal liver metastases: staged versus simultaneous resection?
ANZ Journal of Surgery·2014· 21 cited
page 1 of 7Next →

Frequent Co-authors

Sheung Tat Fan(24), Chung Mau Lo(13), See Ching Chan(9), Tan To Cheung(9), Ksh Chok(9), Roberta Pang(8), Albert Chan(7), Thomas Yau(7), Irene Oi‐Lin Ng(6), Kelvin K. Ng(6), Zhen Yang(6), Pierre Chan(6), John M. Luk(4), David Ho(4), Masatoshi Kudo(3), Jacques Belghiti(3), Steven A. Curley(3), Chi Leung Liu(3), Chi Tat Lam(3), Ching Tung Lum(3)